• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship to further upgrade its state-of-the-art production process for TriMix mRNA immunotherapies

Niel (Belgium), 25 September 2017 — eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by eTheRNA to further develop and optimize its state-of-the-art production process for generating the mRNA components of its TriMix platform, and for clinical trials of innovative and rationally designed mRNA cancer immunotherapies derived from this platform. The improved production process will enable the Company to further reduce its production time and cost of goods and generate more revenues from the production of GMP-grade mRNA for third parties.

The Company’s unique TriMix platform combines three mRNAs encoding proteins that act highly synergistically to activate dendritic cells (DCs), a type of dedicated immune cells also known as antigen presenting cells (APC), to promote enhanced T-cell immunity. In combination with mRNA coding for tumor-specific antigens, TriMix products can also promote an antigen-directed cytotoxic T-cell response.

eTheRNA immunotherapies to present at Sachs Biotech in Europe Forum

Niel (Belgium), 21 September 2017 — eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces that its CEO Dirk Reyn is to present an overview of the company, its novel technologies and development pipeline at the Sachs 17th Biotech in Europe Forum for Global Partnering and Investment.

The presentation will take place on 27 September at 12:15pm in Presentation Track C, which takes place at the Congress Center, Basel, Switzerland.

eTheRNA to appoint Dr. Russell G. Greig as Chairman of the Board

Appointment of highly reputed chairman marks eTheRNA’s ambitions in the cancer immunotherapy area

Dr. Russell G. Greig - Chairman of the Board Niel (Belgium), 14 September 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has appointed Dr. Russell G. Greig as Chairman of the Board. Dr. Greig’s mandate as chairman has become effective as of September 13, 2016.